Evidence map›Paper›PMID 33684789›Full record

ArticleClinical imaging2021

QIBA guidance: Computed tomography imaging for COVID-19 quantitative imaging applications.

Ricardo S Avila, Sean B Fain, Chuck Hatt, Samuel G Armato, James L Mulshine, David Gierada, Mario Silva, David A Lynch, Eric A Hoffman, Frank N Ranallo and 7 more

Abstract read
In one paragraph

Article in Clinical imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ricardo S AvilaAccumetra, LLC, United States of America. Electronic address: rick.avila@accumetra.com.
Sean B FainUniversity of Wisconsin - Madison, United States of America.
Chuck HattImbio, LLC, United States of America; University of Michigan, United States of America.
Samuel G ArmatoUniversity of Chicago, United States of America.
James L MulshineRush University, United States of America.
David GieradaWashington University, United States of America.
Mario SilvaUniversity of Parma, Italy.
David A LynchNational Jewish Health, United States of America.
Eric A HoffmanUniversity of Iowa, United States of America.
Frank N RanalloUniversity of Wisconsin, United States of America.
John R MayoVancouver General Hospital, Canada; The University of British Columbia, Canada.
David YankelevitzMount Sinai Health System, United States of America.
Raul San Jose EsteparBrigham and Women's Hospital, United States of America; Harvard Medical School, United States of America.
Raja SubramaniamMount Sinai Health System, United States of America.
Claudia I HenschkeMount Sinai Health System, United States of America.
Alex GuimaraesOregon Health & Science University, United States of America.
Daniel C SullivanDuke University, United States of America.

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Amy Leanne Ryan · 1998 to 2026
$30.5M
CT and CXR Phenotyping Platform for Assessing COVID-19 Susceptibility and SeverityR21LM013670 · NLM · BRIGHAM AND WOMEN'S HOSPITAL · PI SAN JOSE ESTEPAR, RAUL · 2021 to 2022
$428k
NIDDK NIH HHS P30 DK054759NIEHS NIH HHS P30 ES005605NLM NIH HHS R21 LM013670
6 · The paper itself

Abstract

As the COVID-19 pandemic impacts global populations, computed tomography (CT) lung imaging is being used in many countries to help manage patient care as well as to rapidly identify potentially useful quantitative COVID-19 CT imaging biomarkers. Quantitative COVID-19 CT imaging applications, typically based on computer vision modeling and artificial intelligence algorithms, include the potential for better methods to assess COVID-19 extent and severity, assist with differential diagnosis of COVID-19 versus other respiratory conditions, and predict disease trajectory. To help accelerate the development of robust quantitative imaging algorithms and tools, it is critical that CT imaging is obtained following best practices of the quantitative lung CT imaging community. Toward this end, the Radiological Society of North America's (RSNA) Quantitative Imaging Biomarkers Alliance (QIBA) CT Lung Density Profile Committee and CT Small Lung Nodule Profile Committee developed a set of best practices to guide clinical sites using quantitative imaging solutions and to accelerate the international development of quantitative CT algorithms for COVID-19. This guidance document provides quantitative CT lung imaging recommendations for COVID-19 CT imaging, including recommended CT image acquisition settings for contemporary CT scanners. Additional best practice guidance is provided on scientific publication reporting of quantitative CT imaging methods and the importance of contributing COVID-19 CT imaging datasets to open science research databases.

Indexed as

COVID-19PandemicsArtificial IntelligenceBiomarkersHumansLungSARS-CoV-2Tomography, X-Ray ComputedBiomarkersArtificial intelligenceComputed tomographyCOVID-19Quantitative imaging

Identifiers

PMID33684789
PMCPMC7906537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.